{"paper_id":"50482755-6e8b-48ff-86a7-a1a471f89a33","body_text":"Melatonin: Adjunct therapeutics in ovarian endometrioma\nDOI:\nhttps://doi.org/10.55184/ijpas.v75i03.193Keywords:\nMelatonin receptors, ovarian cycle, ovarian endometrioma, oocyte-embryo quality, signaling pathwaysAbstract\nMelatonin (N-acetyl-5-methoxytryptamine) hormone is a methoxyindole primarily released by the pineal gland. Melatonin has dynamic\nproperties of being a free radical scavenger, inflammatory suppressor, anti-apoptotic agent, reproductive hormone modulator and\nmediator of several signaling pathways in female reproductive system. The presence of differential localization of melatonin receptors\nin the ovary, influence on the ovarian hormones and ovarian cycle has implied the association between ovarian system and melatonin\nboth at the pathological and physiological levels. On the other hand, the pathophysiology of ovarian endometrioma is remarked by\nvarious anomalies likely: generation of various reactive oxygen species, followed by follicular damage, oocyte and embryonic defects,\ninflammation and apoptosis, which the involvement of melatonin can plausibly counteract. The present review evaluated melatonin’s\nprobable protective role against ovarian endometrioma via diverse signaling pathways.","source_license":"CC0","license_restricted":false}